Inhibikase Therapeutics, Inc. (IKT)Healthcare | Biotechnology | Wilmington, United States | NasdaqCM
2.41 USD
-0.06
(-2.429%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.41 |
Hot Take ↕ | Aug. 22, 2026, 3:12 a.m. EDT
The immediate outlook remains neutral due to a lack of clear directional momentum, despite the stock trading above its 50-day average. However, the long-term investment case is severely compromised by a brutal four-year price trajectory that has erased over 84% of shareholder value, driven by three consecutive years of double-digit declines before a single year of recovery. While the company boasts a fortress balance sheet with a current ratio of nearly 16 and significant cash reserves, these defensive metrics cannot offset the reality that the market has punished the business repeatedly, and the negative earnings per share indicate ongoing operational losses. Furthermore, the absence of any dividend payments eliminates income potential, leaving investors entirely exposed to capital appreciation in a sector where the recent price action suggests continued volatility rather than a sustainable rebound. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.167967 |
| AutoTheta | 0.181790 |
| AutoETS | 0.181897 |
| AutoARIMA | 0.181898 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 27.34 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.319 |
| Excess Kurtosis | -1.06 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 336,281,536 |
| Forward P/E | -5.57 |
| Beta | 0.95 |
| Website | https://www.inhibikase.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.36931813 |
| Address1 | 1,000 N. West Street |
| Address2 | Suite 1200 |
| All Time High | 70.8 |
| All Time Low | 0.79 |
| Ask | 3.07 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 427,000 |
| Average Daily Volume3 Month | 781,495 |
| Average Volume | 781,495 |
| Average Volume10Days | 427,000 |
| Beta | 0.952 |
| Bid | 2.38 |
| Bid Size | 1 |
| Board Risk | 9 |
| Book Value | 0.878 |
| City | Wilmington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.41 |
| Current Ratio | 15.823 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.48 |
| Day Low | 2.371 |
| Display Name | Inhibikase Therapeutics |
| Earnings Call Timestamp End | 1,723,723,200 |
| Earnings Call Timestamp Start | 1,723,723,200 |
| Earnings Timestamp End | 1,794,600,000 |
| Earnings Timestamp Start | 1,794,600,000 |
| Ebitda | -66,164,280 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.229 |
| Enterprise Value | 279,781,440 |
| Eps Current Year | -0.445 |
| Eps Forward | -0.4325 |
| Eps Trailing Twelve Months | -0.43 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.2098 |
| Fifty Day Average Change | 0.20020008 |
| Fifty Day Average Change Percent | 0.09059647 |
| Fifty Two Week Change Percent | 36.931812 |
| Fifty Two Week High | 2.54 |
| Fifty Two Week High Change | -0.12999988 |
| Fifty Two Week High Change Percent | -0.051181056 |
| Fifty Two Week Low | 1.33 |
| Fifty Two Week Low Change | 1.08 |
| Fifty Two Week Low Change Percent | 0.8120301 |
| Fifty Two Week Range | 1.33 - 2.54 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,608,733,800,000 |
| Float Shares | 107,134,639 |
| Forward Eps | -0.4325 |
| Forward P E | -5.5722547 |
| Free Cashflow | -22,095,724 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 35 |
| Fullday Change | -0.0599999 |
| Fullday Change Percent | -2.42915 |
| Fullday Price | 2.41 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06091 |
| Held Percent Institutions | 0.92218 |
| Implied Shares Outstanding | 139,535,900 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-12-23 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,688,083,200 |
| Last Split Factor | 1:6 |
| Long Business Summary | Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware. |
| Long Name | Inhibikase Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 336,281,536 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_113910012 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -60,637,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 346,049,032 |
| Number Of Analyst Opinions | 9 |
| Open | 2.48 |
| Operating Cashflow | -42,612,036 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 302 295 3800 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.41 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 2.47 |
| Price Eps Current Year | -5.4157305 |
| Price Hint | 4 |
| Price To Book | 2.7448747 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.499 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0599999 |
| Regular Market Change Percent | -2.42915 |
| Regular Market Day High | 2.48 |
| Regular Market Day Low | 2.371 |
| Regular Market Day Range | 2.371 - 2.48 |
| Regular Market Open | 2.48 |
| Regular Market Previous Close | 2.47 |
| Regular Market Price | 2.41 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 307,959 |
| Return On Assets | -0.32789 |
| Return On Equity | -0.51964 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 9 |
| Shares Outstanding | 139,535,900 |
| Shares Percent Shares Out | 0.1409 |
| Shares Short | 19,666,839 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 18,261,416 |
| Short Name | Inhibikase Therapeutics, Inc. |
| Short Percent Of Float | 0.2195 |
| Short Ratio | 21.91 |
| Source Interval | 15 |
| State | DE |
| Symbol | IKT |
| Target High Price | 8.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 6.0 |
| Target Median Price | 6.0 |
| Total Cash | 159,018,848 |
| Total Cash Per Share | 0.873 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.43 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.8539 |
| Two Hundred Day Average Change | 0.55610013 |
| Two Hundred Day Average Change Percent | 0.2999623 |
| Type Disp | Equity |
| Volume | 307,959 |
| Website | https://www.inhibikase.com |
| Zip | 19,801 |